Joint Clinical Trials Office

You are here

RPC01-3102: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis. (Extension study for RPC01-3101)

Clinical Trial Details

The purpose of this study is to see if long-term use of the investigational drug RPC1063 (ozanimod) is safe and effective for the possible treatment of UC. 
    
RPC1063 is a chemical compound that is thought to act on the immune system by making certain types of white blood cells (lymphocytes including T cells) stay in the lymph nodes and other places in the body, keeping them away from sites of inflammation. 
    
This is a Phase III study, which means that the study drug has already been tested in humans for safety and effectiveness but now is being tested in a larger number of patients 

Key Eligibility: 

Inclusion Criteria: 

  • Previous participation on a trial of RPC1063 for ulcerative colitis (UC) and may benefit from continued treatment 

Exclusion Criteria: 

  • Require initiation of other therapies used in the treatment of UC 
  • Pregnant, lactating, or have a positive serum pregnancy test 
  • Have clinically relevant cardiovascular conditions or other relevant disease that would put the patient at risk or make interpretation of the trial difficult 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Fatiha Chabouni
(212) 746-5109
fac2005@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1508016523

ClinicalTrials.gov:

NCT02531126

Status

Open to Enrollment

Age Group

Adult

Sponsor